{"id":"ac-203","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Activation of the kappa opioid receptor is thought to produce analgesia with a lower risk of respiratory depression compared to mu opioid receptor agonists. AC-203 has been investigated for its potential to treat pain in various conditions.","oneSentence":"AC-203 is a selective agonist of the kappa opioid receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:33.374Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain"}]},"trialDetails":[{"nctId":"NCT06073132","phase":"PHASE2, PHASE3","title":"An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)","status":"RECRUITING","sponsor":"TWi Biotechnology, Inc.","startDate":"2024-04-04","conditions":"Generalized Epidermolysis Bullosa Simplex","enrollment":80},{"nctId":"NCT03286582","phase":"PHASE2","title":"A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid","status":"TERMINATED","sponsor":"TWi Biotechnology, Inc.","startDate":"2017-09-05","conditions":"Bullous Pemphigoid","enrollment":10},{"nctId":"NCT03468322","phase":"PHASE2","title":"A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients","status":"COMPLETED","sponsor":"TWi Biotechnology, Inc.","startDate":"2018-10-20","conditions":"Inherited Epidermolysis Bullosa","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AC-203","genericName":"AC-203","companyName":"TWi Biotechnology, Inc.","companyId":"twi-biotechnology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AC-203 is a selective agonist of the kappa opioid receptor. Used for Chronic pain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}